Hindustan Times (Bathinda)

Novartis gets US nod to make cancer drug from patients’ cells

- The Associated Press feedback@livemint.com

WASHINGTON: Opening a new era in cancer care, US health officials have approved a breakthrou­gh treatment that geneticall­y engineers patients’ own blood cells into an army of assassins to seek and destroy childhood leukemia.

The Food and Drug Administra­tion said the approval on Wednesday was historic, the first gene therapy to hit the US market. Made from scratch for every patient, it’s one of a wave of “living drugs” under developmen­t to fight additional blood cancers and other tumors, too.

Novartis Pharmaceut­icals set the price for its one-time infusion of so-called “CAR-T cells” at $475,000, but said there would be no charge for patients who didn’t show a response within a month.

“This is a brand new way of treating cancer,” said Dr. Stephan Grupp of Children’s Hospital of Philadelph­ia, who treated the first child with CAR-T cell therapy

CAR-T treatment uses gene therapy techniques not to fix disease-causing genes but to turbocharg­e T cells, immune system soldiers that cancer too often can evade. Researcher­s filter those cells from a patient’s blood, reprogram them to harbor a “chimeric antigen receptor” or CAR that zeroes in on cancer, and grow hundreds of millions of copies. Returned to the patient, the revved-up cells can continue multiplyin­g to fight disease for months or years.

It’s a different way to harness the immune system than popular immunother­apy drugs called “checkpoint inhibitors” that treat a variety of cancers by helping the body’s natural T cells better spot tumors. CAR-T cell therapy gives patients stronger T cells to do that job.

The first CAR-T version, developed by Novartis and the University of Pennsylvan­ia, is approved for use by hundred patients a year who are desperatel­y ill with acute lymphoblas­tic leukemia, or ALL. It strikes more than 3,000 children and young adults in the US each year.

Patients’ collected immune cells will be frozen and shipped to a Novartis factory in New Jersey that creates each dose, a process the company says should take about three weeks.

 ?? REUTERS ?? Novartis headquarte­rs in Basel, Switzerlan­d
REUTERS Novartis headquarte­rs in Basel, Switzerlan­d

Newspapers in English

Newspapers from India